Phase II Clinical Trial of Monthly Triptorelin Injection for Prostate Cancer
每月注射Triptorelin治療前列腺癌—第二相臨床試驗
Journal
中華民國泌尿科醫學會雜誌
Journal Volume
8
Journal Issue
1
Pages
7-13
Date Issued
1997
Author(s)
Abstract
Ten patients with prostate adenocarcinoma entered into the phase II clinical trial and treated with monthly intramuscular 3.75 mg triptorelin injection to assess its efficacy in suppressing tunmor progression and side effects. null All patients were given one to three weeks of antiandrogen to inhibit the possible flare-up by the initiation of triptorelin. null In results, one patient died of disseminated prostate cancer in the study period, indicating treatment failure. null The other 9 patients alive after 6 to 10 months of treatment were considered as being responders by the modified Eastern Cooperative Oncology Group Tumor Response Criteria and prostate specific antigen (PSA) criteria. null Of the 6 patients with measurable lesions, 5 had objective response (2 CR and 3 PR). null All but the case of failure had more than 50% PSA reduction (range:90% to 100%) for 8 weeks or more. null All the 9 responding patients had improvement or stabilization of the Karnofsky performance status. null Of the 7 patients with complete hormonal profile checked, 5 showed significant suppression of luteinizing hormone (LH) and testosterone after 2 to 3 months of treatment. null The other 2 showed no evident suppression of testosterone or LH levels, although their PSA’s declined for 90% and 100%, respectively. null Only two patients had evident improvement in bone scanning as shown by the resolution of previous metastatic hot spots. null All the 9 responding patients turned sexually impotent after 6 months of triptorelin treatment. null null One complained of hot flush, hand and foot swelling, night sweating and dizziness, which were considered as typical side effects of triptorelin as well as other forms of gonadotropin releasing hormone agonists. null In conclusion, monthly triptorelin treatment is effective in suppressing prostate cancer progression and causes negligible side effects in most patients with prostate adenocarcinoma.
SDGs
Type
journal article